| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 51.10 | 140.18 | 133.34 | 88.76 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 56.13 | 143.73 | 135.69 | 93.09 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.97 | 5.83 | 3.63 | 3.21 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 3.90 | 11.58 | 18.34 | 11.79 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (22.61) | (22.68) | — | — |
—
|
| ’25 | (16.06) | (17.71) | (14.48) | (14.09) |
(62.34)
|
| ’24 | (8.74) | (7.77) | (11.77) | (18.99) |
(47.27)
|
| ’23 | (9.92) | (8.22) | (12.25) | (9.13) |
(39.53)
|
| ’22 | (8.16) | (6.22) | (4.57) | (9.48) |
(28.42)
|
| ’21 | (5.17) | (7.45) | (7.09) | (9.21) |
(28.91)
|
| ’20 | (2.20) | (3.02) | (0.56) | (9.43) |
(15.21)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (22.61) | (22.68) | — | — |
—
|
| ’25 | (16.06) | (17.71) | (14.48) | (14.09) |
(62.34)
|
| ’24 | (8.74) | (7.77) | (11.77) | (18.99) |
(47.27)
|
| ’23 | (9.92) | (8.22) | (12.25) | (9.13) |
(39.53)
|
| ’22 | (8.16) | (6.22) | (4.57) | (9.48) |
(28.42)
|
| ’21 | (5.17) | (7.45) | (7.09) | (9.21) |
(28.91)
|
| ’20 | (2.20) | (3.02) | (0.56) | (9.43) |
(15.21)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.33) | (0.27) | — | — |
—
|
| ’25 | (0.08) | (0.13) | (0.21) | (0.10) |
(0.52)
|
| ’24 | (0.34) | (1.06) | (0.32) | (0.64) |
(0.75)
|
| ’23 | (0.75) | (0.40) | (0.35) | (0.29) |
(1.64)
|
| ’22 | (0.69) | (0.65) | (0.73) | (4.09) |
(6.16)
|
| ’21 | (0.57) | (0.50) | (0.66) | (0.59) |
(2.33)
|
| ’20 | (8.45) | (2.70) | (5.51) | (0.39) |
(15.72)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | 2.03 | 1.07 | 1.52 | 1.35 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.14 | 3.70 | 5.54 | 4.98 | — | — | — |
High Price
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 17 | 20 | 31 | 33 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (87.97) | (116.54) | (35.75) | (45.58) | ‡‡‡‡‡ | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (87.97) | (116.54) | (36.18) | (45.62) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 49.02 | 0.37 | 0.36 | — | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (6.16) | (1.64) | (0.75) | (0.52) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.99) | (1.61) | (0.97) | (0.76) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.99) | (1.61) | (0.97) | (0.76) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.89 | 0.29 | 2.43 | 1.67 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 14.29 | 24.62 | 48.54 | 81.84 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | — | — |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (28.42) | (39.53) | (47.27) | (62.34) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (28.42) | (39.53) | (47.27) | (62.34) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 53.04 | 52.23 | 132.15 | 117.34 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.75 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (55.66) | (51.10) | (140.18) | (133.34) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 84.18 | 7.21 | 118.14 | 136.78 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (66.81%) | (128.16%) | (27.16%) | (26.34%) | ‡‡‡‡‡ | — | — |
ROA
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (193.79%) | 0.00% | 0.00% | (1,511.24%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (70.89%) | (652.92%) | (518.40%) | (63.56%) | ‡‡‡‡‡ | — | — |
ROE
|
Eledon Pharmaceuticals (ELDN), a clinical-stage biotech targeting organ transplant rejection with its lead anti-CD40L antibody tegoprubart, trades at depressed levels around $2, reflecting a 98% plunge from 2016 peaks amid relentless cash burn and 64x share dilution to 48.5 million. Despite deepening losses—$116.5 million in 2023—and zero revenue until 2025 projections of $25 million, the company boasts a robust $140 million net cash position, funding runway into 2027. Analyst consensus screams upside: average 320% potential from current prices, with highs at 500% and lows at 100%, fueled by promising Phase 2 transplant data.
Financial red flags abound—negative ROE of -5.18%, free cash flow per share near -$1, and projected EPS worsening to -$0.90 in 2025 amid further dilution to 79 million shares—yet correlations tie price crashes to trial delays and impairments, with recent stabilization hinting at a bottom. Insider silence adds neutrality, but key catalysts loom: 2025-2026 Phase 2b TRANSLATE readout could mirror peer surges, unlocking partnerships and revenue inflection.
This high-risk profile blends biotech peril (value destruction, dilution traps) with explosive reward if tegoprubart succeeds—potentially 5x like past hype cycles. For risk-tolerant investors, small positions await milestones; dilution over 10% quarterly or trial slips spell exit. Dive deeper for patterns, probabilities, and portfolio math.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.